PAREXEL Wins Best Technological Development in Clinical Trial Award at the 11th Annual Scrip Awards
December 18 2015 - 9:00AM
Business Wire
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services provider, announced today that
its Country Allocation Technology won the Best Technological
Development in Clinical Trials Award at the 2015 Scrip Awards. The
award recognizes the importance of PAREXEL’s Country Allocation
Technology across the drug development value chain.
Country selection, patient recruitment, and patient enrollment
are among the most fundamental needs in drug development. Delays in
one of these areas can cost a biopharmaceutical company time and
money in getting a new drug to a patient in need. To address this
challenge, PAREXEL developed its Country Allocation Technology,
providing feasibility teams a data-driven tool for country
selection.
“This award honors PAREXEL’s long history of innovation in
clinical trial technology,” said Paul Evans, Vice President, Site
Strategy & Start-Up, PAREXEL. “Our Country Allocation
Technology provides a data-driven approach to country selection for
a clinical trial. By looking at a variety of data, we provide
clients with a clear ranking of countries for their specific trial
based on medical, clinical, operational, regulatory, and financial
criteria.”
PAREXEL was one of six finalists in the Best Technological
Development in Clinical Trials category, which focused on
identifying the product that represents the best advance in
supporting clinical trial management. In selecting PAREXEL as the
winner, the judges explained: “The cost savings are massive. If we
can get the feasibility right, we can progress studies more
efficiently.”
“At PAREXEL, we believe the world would be a healthier place if
the journey between science and new treatments were simpler. We
innovate continuously to provide technology services that empower
our clients to make data-driven business decisions, helping to
reduce risk and to speed time to market,” added David Kiger, Vice
President, Product Strategy, PAREXEL Informatics.
About the Scrip Awards Best Technological
Development in Clinical Trials Award
The Best Technological Development in Clinical Trials Award
recognizes the vital importance of using the most sophisticated
platforms to catalyze and optimize data gathering during clinical
trials. It celebrates the advances in software and applications
that are playing a pivotal role in the trial process, from patient
recruitment and compliance, to managing and mining outcomes or
safety data.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics provides advanced
technology solutions, including medical imaging, to facilitate the
clinical development process. Headquartered near Boston,
Massachusetts, PAREXEL has offices in 80 locations in 51 countries
around the world, and had approximately 18,620 employees in the
first quarter. For more information about PAREXEL International
visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20151218005060/en/
PAREXEL InternationalCristi Barnett, +1
781-434-4019Cristi.Barnett@PAREXEL.comorPAN CommunicationsMatthew
Briggs, +1 617-502-4300PAREXEL@pancomm.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024